Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy

SEATTLE--(BUSINESS WIRE)--Apr 10, 2024--

Related Keywords

United States ,Argentina ,Buenos Aires ,Distrito Federal ,James Tumlin ,Nasdaq ,Linkedin ,Alpine Immune Sciences ,Nephronet Clinical Trials Consortium ,Buenos Aires Convention Center ,Exchange Commission ,Securities Exchange ,Vertex Pharmaceuticals Incorporated ,World Congress ,Alpine Immune Sciences Inc ,Immune Sciences ,Clinically Meaningful ,Iga Nephropathy ,Business Wire ,Highlights Include ,Nephrology Late Breaking ,Updated Results ,Enhanced Dual ,Poster Session ,Late Breaking ,Exhibition Hall ,Main Foyer ,Emory University School ,Nephronet Clinical Trials ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Recommendation Statement ,Investor Relations Contact ,